GlaxoSmithKline PLC Director/PDMR Shareholding (0192D)
April 21 2017 - 8:36AM
UK Regulatory
TIDMGSK
RNS Number : 0192D
GlaxoSmithKline PLC
21 April 2017
GlaxoSmithKline plc (the 'Company')
Transaction notification
1. Details of PDMR/person closely associated with them
('PCA')
=== ==========================================================================
a) Name Ms E Walmsley
=== ======================== ================================================
b) Position/status Chief Executive Officer
=== ======================== ================================================
c) Initial notification/ Initial notification
amendment
=== ======================== ================================================
2. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
=== ==========================================================================
a) Name GlaxoSmithKline plc
=== ======================== ================================================
b) LEI 5493000HZTVUYLO1D793
=== ======================== ================================================
3. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transaction(s)
has been conducted
=== ==========================================================================
a) Description of Ordinary shares of 25 pence each ('Ordinary
the financial Shares')
instrument ISIN: GB0009252882
=== ======================== ================================================
b) Nature of the Increase in notional interest in Ordinary
transaction Shares following the re-investment of dividends
paid to shareholders on 13 April 2017 on
Ordinary Shares held in the Company's 2009
Performance Share Plan.
=== ======================== ================================================
c) Price(s) and Price(s) Volume(s)
volume(s) ---------- ----------
GBP16.47 910.450
---------- ----------
GBP16.47 1,756.522
---------- ----------
GBP16.47 2,998.638
---------- ----------
=== ======================== ================================================
d) Aggregated information
Aggregated volume
Price
5,665.610
GBP16.47
=== ======================== ================================================
e) Date of the transaction 2017-04-18
=== ======================== ================================================
f) Place of the n/a
transaction
=== ======================== ================================================
1. Details of PDMR/person closely associated with them
('PCA')
=== ==========================================================================
a) Name Mr R G Connor
=== ======================== ================================================
b) Position/status President, Global Manufacturing & Supply
=== ======================== ================================================
c) Initial notification/ Initial notification
amendment
=== ======================== ================================================
2. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
=== ==========================================================================
a) Name GlaxoSmithKline plc
=== ======================== ================================================
b) LEI 5493000HZTVUYLO1D793
=== ======================== ================================================
3. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transaction(s)
has been conducted
=== ==========================================================================
a) Description of Ordinary shares of 25 pence each ('Ordinary
the financial Shares')
instrument ISIN: GB0009252882
=== ======================== ================================================
b) Nature of the Increase in notional interest in Ordinary
transaction Shares following the re-investment of dividends
paid to shareholders on 13 April 2017 on
Ordinary Shares held in the Company's 2009
Performance Share Plan.
=== ======================== ================================================
c) Price(s) and Price(s) Volume(s)
volume(s) ---------- ----------
GBP16.47 1,367.102
---------- ----------
GBP16.47 1,752.027
---------- ----------
=== ======================== ================================================
d) Aggregated information
Aggregated volume
Price
3,119.129
GBP16.47
=== ======================== ================================================
e) Date of the transaction 2017-04-18
=== ======================== ================================================
f) Place of the n/a
transaction
=== ======================== ================================================
1. Details of PDMR/person closely associated with them
('PCA')
=== ==========================================================================
a) Name Mr L Debruyne
=== ======================== ================================================
b) Position/status President, Global Vaccines
=== ======================== ================================================
c) Initial notification/ Initial notification
amendment
=== ======================== ================================================
2. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
=== ==========================================================================
a) Name GlaxoSmithKline plc
=== ======================== ================================================
b) LEI 5493000HZTVUYLO1D793
=== ======================== ================================================
3. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transaction(s)
has been conducted
=== ==========================================================================
a) Description of Ordinary shares of 25 pence each ('Ordinary
the financial Shares')
instrument ISIN: GB0009252882
=== ======================== ================================================
b) Nature of the Increase in notional interest in Ordinary
transaction Shares following the re-investment of dividends
paid to shareholders on 13 April 2017 on
Ordinary Shares held in the Company's 2009
Performance Share Plan.
=== ======================== ================================================
c) Price(s) and Price(s) Volume(s)
volume(s) ---------- ----------
GBP16.47 349.698
---------- ----------
GBP16.47 440.757
---------- ----------
=== ======================== ================================================
d) Aggregated information
Aggregated volume
Price
790.455
GBP16.47
=== ======================== ================================================
e) Date of the transaction 2017-04-18
=== ======================== ================================================
f) Place of the n/a
transaction
=== ======================== ================================================
1. Details of PDMR/person closely associated with them
('PCA')
=== ==========================================================================
a) Name Mr S Dingemans
=== ======================== ================================================
b) Position/status Chief Financial Officer
=== ======================== ================================================
c) Initial notification/ Initial notification
amendment
=== ======================== ================================================
2. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
=== ==========================================================================
a) Name GlaxoSmithKline plc
=== ======================== ================================================
b) LEI 5493000HZTVUYLO1D793
=== ======================== ================================================
3. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transaction(s)
has been conducted
=== ==========================================================================
a) Description of Ordinary shares of 25 pence each ('Ordinary
the financial Shares')
instrument ISIN: GB0009252882
=== ======================== ================================================
b) Nature of the Increase in notional interest in Ordinary
transaction Shares following the re-investment of dividends
paid to shareholders on 13 April 2017 on
Ordinary Shares held in the Company's 2009
Performance Share Plan.
=== ======================== ================================================
c) Price(s) and Price(s) Volume(s)
volume(s) ---------- ----------
GBP16.47 2,973.255
---------- ----------
GBP16.47 3,220.155
---------- ----------
=== ======================== ================================================
d) Aggregated information
Aggregated volume
Price
6,193.410
GBP16.47
=== ======================== ================================================
e) Date of the transaction 2017-04-18
=== ======================== ================================================
f) Place of the n/a
transaction
=== ======================== ================================================
1. Details of PDMR/person closely associated with them
('PCA')
=== ==========================================================================
a) Name Mr N Hirons
=== ======================== ================================================
b) Position/status SVP, Global Ethics & Compliance
=== ======================== ================================================
c) Initial notification/ Initial notification
amendment
=== ======================== ================================================
2. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
=== ==========================================================================
a) Name GlaxoSmithKline plc
=== ======================== ================================================
b) LEI 5493000HZTVUYLO1D793
=== ======================== ================================================
3. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transaction(s)
has been conducted
=== ==========================================================================
a) Description of Ordinary shares of 25 pence each ('Ordinary
the financial Shares')
instrument ISIN: GB0009252882
=== ======================== ================================================
b) Nature of the Increase in notional interest in Ordinary
transaction Shares following the re-investment of dividends
paid to shareholders on 13 April 2017 on
Ordinary Shares held in the Company's 2009
Performance Share Plan.
=== ======================== ================================================
c) Price(s) and Price(s) Volume(s)
volume(s) ---------- ----------
GBP16.47 662.840
---------- ----------
GBP16.47 722.300
---------- ----------
=== ======================== ================================================
d) Aggregated information
Aggregated volume
Price
1,385.140
GBP16.47
=== ======================== ================================================
e) Date of the transaction 2017-04-18
=== ======================== ================================================
f) Place of the n/a
transaction
=== ======================== ================================================
1. Details of PDMR/person closely associated with them
('PCA')
=== ==========================================================================
a) Name Mr S A Hussain
=== ======================== ================================================
b) Position/status President, Global Pharmaceuticals
=== ======================== ================================================
c) Initial notification/ Initial notification
amendment
=== ======================== ================================================
2. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
=== ==========================================================================
a) Name GlaxoSmithKline plc
=== ======================== ================================================
b) LEI 5493000HZTVUYLO1D793
=== ======================== ================================================
3. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transaction(s)
has been conducted
=== ==========================================================================
a) Description of Ordinary shares of 25 pence each ('Ordinary
the financial Shares')
instrument ISIN: GB0009252882
=== ======================== ================================================
b) Nature of the Increase in notional interest in Ordinary
transaction Shares following the re-investment of dividends
paid to shareholders on 13 April 2017 on
Ordinary Shares held in the Company's 2009
Performance Share Plan.
=== ======================== ================================================
c) Price(s) and Price(s) Volume(s)
volume(s) ---------- ----------
GBP16.47 3,107.069
---------- ----------
GBP16.47 3,502.071
---------- ----------
=== ======================== ================================================
d) Aggregated information
Aggregated volume
Price
6,609.140
GBP16.47
=== ======================== ================================================
e) Date of the transaction 2017-04-18
=== ======================== ================================================
f) Place of the n/a
transaction
=== ======================== ================================================
1. Details of PDMR/person closely associated with them
('PCA')
=== ==========================================================================
a) Name Mr D S Redfern
=== ======================== ================================================
b) Position/status Chief Strategy Officer
=== ======================== ================================================
c) Initial notification/ Initial notification
amendment
=== ======================== ================================================
2. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
=== ==========================================================================
a) Name GlaxoSmithKline plc
=== ======================== ================================================
b) LEI 5493000HZTVUYLO1D793
=== ======================== ================================================
3. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transaction(s)
has been conducted
=== ==========================================================================
a) Description of Ordinary shares of 25 pence each ('Ordinary
the financial Shares')
instrument ISIN: GB0009252882
=== ======================== ================================================
b) Nature of the Increase in notional interest in Ordinary
transaction Shares following the re-investment of dividends
paid to shareholders on 13 April 2017 on
Ordinary Shares held in the Company's 2009
Performance Share Plan.
=== ======================== ================================================
c) Price(s) and Price(s) Volume(s)
volume(s) ---------- ----------
GBP16.47 1,087.465
---------- ----------
GBP16.47 1,269.488
---------- ----------
=== ======================== ================================================
d) Aggregated information
Aggregated volume
Price
2,356.953
GBP16.47
=== ======================== ================================================
e) Date of the transaction 2017-04-18
=== ======================== ================================================
f) Place of the n/a
transaction
=== ======================== ================================================
1. Details of PDMR/person closely associated with them
('PCA')
=== ==========================================================================
a) Name Ms C Thomas
=== ======================== ================================================
b) Position/status SVP, HR
=== ======================== ================================================
c) Initial notification/ Initial notification
amendment
=== ======================== ================================================
2. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
=== ==========================================================================
a) Name GlaxoSmithKline plc
=== ======================== ================================================
b) LEI 5493000HZTVUYLO1D793
=== ======================== ================================================
3. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transaction(s)
has been conducted
=== ==========================================================================
a) Description of Ordinary shares of 25 pence each ('Ordinary
the financial Shares')
instrument ISIN: GB0009252882
=== ======================== ================================================
b) Nature of the Increase in notional interest in Ordinary
transaction Shares following the re-investment of dividends
paid to shareholders on 13 April 2017 on
Ordinary Shares held in the Company's 2009
Performance Share Plan.
=== ======================== ================================================
c) Price(s) and Price(s) Volume(s)
volume(s) ---------- ----------
GBP16.47 1,449.959
---------- ----------
GBP16.47 1,597.807
---------- ----------
=== ======================== ================================================
d) Aggregated information
Aggregated volume
Price
3,047.766
GBP16.47
=== ======================== ================================================
e) Date of the transaction 2017-04-18
=== ======================== ================================================
f) Place of the n/a
transaction
=== ======================== ================================================
1. Details of PDMR/person closely associated with them
('PCA')
=== ============================================================================
a) Name Mr P C Thomson
=== ========================== ================================================
b) Position/status President, Global Affairs
=== ======================== ==================================================
c) Initial notification/ Initial notification
amendment
=== ========================== ================================================
2. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
=== ============================================================================
a) Name GlaxoSmithKline plc
=== ========================== ================================================
b) LEI 5493000HZTVUYLO1D793
=== ========================== ================================================
3. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transaction(s)
has been conducted
=== ============================================================================
a) Description of Ordinary shares of 25 pence each ('Ordinary
the financial Shares')
instrument ISIN: GB0009252882
=== ========================== ================================================
b) Nature of the Increase in notional interest in Ordinary
transaction Shares following the re-investment of dividends
paid to shareholders on 13 April 2017 on
Ordinary Shares held in the Company's 2009
Performance Share Plan.
=== ========================== ================================================
c) Price(s) and Price(s) Volume(s)
volume(s) ---------- ----------
GBP16.47 838.910
---------- ----------
GBP16.47 919.292
---------- ----------
=== ========================== ================================================
d) Aggregated information
Aggregated volume
Price
1,758.202
GBP16.47
=== ========================== ================================================
e) Date of the transaction 2017-04-18
=== ========================== ================================================
f) Place of the n/a
transaction
=== ========================== ================================================
1. Details of PDMR/person closely associated with them
('PCA')
=== ==========================================================================
a) Name Dr P J T Vallance
=== ======================== ================================================
b) Position/status President, R&D
=== ======================== ================================================
c) Initial notification/ Initial notification
amendment
=== ======================== ================================================
2. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
=== ==========================================================================
a) Name GlaxoSmithKline plc
=== ======================== ================================================
b) LEI 5493000HZTVUYLO1D793
=== ======================== ================================================
3. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transaction(s)
has been conducted
=== ==========================================================================
a) Description of Ordinary shares of 25 pence each ('Ordinary
the financial Shares')
instrument ISIN: GB0009252882
=== ======================== ================================================
b) Nature of the Increase in notional interest in Ordinary
transaction Shares following the re-investment of dividends
paid to shareholders on 13 April 2017 on
Ordinary Shares held in the Company's 2009
Performance Share Plan.
=== ======================== ================================================
c) Price(s) and Price(s) Volume(s)
volume(s) ---------- ----------
GBP16.47 3,015.919
---------- ----------
GBP16.47 3,720.939
---------- ----------
=== ======================== ================================================
d) Aggregated information
Aggregated volume
Price
6,736.858
GBP16.47
=== ======================== ================================================
e) Date of the transaction 2017-04-18
=== ======================== ================================================
f) Place of the n/a
transaction
=== ======================== ================================================
1. Details of PDMR/person closely associated with them
('PCA')
=== ==========================================================================
a) Name Mrs V A Whyte
=== ======================== ================================================
b) Position/status Company Secretary
=== ======================== ================================================
c) Initial notification/ Initial notification
amendment
=== ======================== ================================================
2. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
=== ==========================================================================
a) Name GlaxoSmithKline plc
=== ======================== ================================================
b) LEI 5493000HZTVUYLO1D793
=== ======================== ================================================
3. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transaction(s)
has been conducted
=== ==========================================================================
a) Description of Ordinary shares of 25 pence each ('Ordinary
the financial Shares')
instrument ISIN: GB0009252882
=== ======================== ================================================
b) Nature of the Increase in notional interest in Ordinary
transaction Shares following the re-investment of dividends
paid to shareholders on 13 April 2017 on
Ordinary Shares held in the Company's 2009
Performance Share Plan.
=== ======================== ================================================
c) Price(s) and Price(s) Volume(s)
volume(s) ---------- ----------
GBP16.47 175.499
---------- ----------
GBP16.47 185.700
---------- ----------
=== ======================== ================================================
d) Aggregated information
Aggregated volume
Price
361.199
GBP16.47
=== ======================== ================================================
e) Date of the transaction 2017-04-18
=== ======================== ================================================
f) Place of the n/a
transaction
=== ======================== ================================================
This information is provided by RNS
The company news service from the London Stock Exchange
END
DSHLFLFLDZFXBBZ
(END) Dow Jones Newswires
April 21, 2017 08:36 ET (12:36 GMT)
Gsk (LSE:GSK)
Historical Stock Chart
From Mar 2024 to Apr 2024
Gsk (LSE:GSK)
Historical Stock Chart
From Apr 2023 to Apr 2024
